Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) Stock Has Consensus Target Price of $16.80

Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI – Get Free Report) has earned an average rating of “Buy” from the six analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $16.80.

A number of brokerages have weighed in on LMRI. KeyCorp initiated coverage on shares of Lumexa Imaging in a report on Thursday, September 24th. They issued an “overweight” rating and a $18.00 price target for the company. Deutsche Bank set a $16.00 price target on shares of Lumexa Imaging in a research report on Thursday, August 13th. Weiss Ratings downgraded shares of Lumexa Imaging from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday. Wall Street Zen upgraded shares of Lumexa Imaging from a “hold” rating to a “buy” rating in a report on Saturday, October 3rd. Finally, Truist Financial began coverage on shares of Lumexa Imaging in a research report on Monday, October 5th. They set a “buy” rating and a $18.00 price objective for the company.

View Our Latest Stock Analysis on LMRI

Lumexa Imaging Stock Down 0.1%

LMRI opened at $14.79 on Tuesday. The business has a 50 day moving average of $11.50 and a 200-day moving average of $11.09. The stock has a market capitalization of $1.42 billion and a price-to-earnings ratio of -27.39. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 1.40. Lumexa Imaging has a 1-year low of $6.45 and a 1-year high of $19.45.

Lumexa Imaging (NASDAQ:LMRI – Get Free Report) last announced its earnings results on Tuesday, November 10th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $0.19. Lumexa Imaging had a negative net margin of 1.96% and a negative return on equity of 2.93%. The business had revenue of $271.97 million for the quarter. As a group, sell-side analysts anticipate that Lumexa Imaging will post 0.22 earnings per share for the current year.

Hedge Funds Weigh In On Lumexa Imaging

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. State of Alaska Department of Revenue bought a new position in Lumexa Imaging during the third quarter valued at about $46,000. PNC Financial Services Group Inc. bought a new stake in shares of Lumexa Imaging in the 1st quarter worth approximately $63,000. State of Wyoming bought a new stake in shares of Lumexa Imaging in the 1st quarter worth approximately $91,000. AXQ Capital LP acquired a new stake in shares of Lumexa Imaging during the 2nd quarter worth approximately $128,000. Finally, Pathstone Holdings LLC acquired a new stake in shares of Lumexa Imaging during the 3rd quarter worth approximately $193,000.

Lumexa Imaging Company Profile

(Get Free Report)

Lumexa Imaging operates outpatient diagnostic imaging centers that provide radiology services to patients, referring physicians and healthcare providers. Its services include imaging used to help diagnose and monitor a range of medical conditions. The company offers diagnostic procedures such as MRI, CT, PET/CT, mammography, ultrasound and X-ray through its imaging centers and affiliated radiology practices. Lumexa serves communities across the United States, providing an outpatient option for medical imaging outside of a hospital setting.

See Also

Analyst Recommendations for Lumexa Imaging (NASDAQ:LMRI)

Receive News & Ratings for Lumexa Imaging Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumexa Imaging and related companies with MarketBeat.com's FREE daily email newsletter.